Quick use of anticoagulants saves heart patients’ lives
When anticoagulants are administered quickly, the chances of complications after a heart attack diminish markedly. If anticoagulants are given on board an ambulance, it’s even possible to avert a heart attack which will decrease the number of deaths due to them. This conclusion follows from research in the Netherlands by cardiologist Ton Heestermans involving a group of 984 heart patients. Heestermans published earlier on his research in British medical journal The Lancet. Heestermans will be awarded a PhD for his research on 30 June 2010 by the University of Groningen.
Heestermans followed 984 heart patients for an extended period of time. Administering anticoagulants as early as possible meant that a necessary angioplasty treatment could not only be conducted more safely but also be done better. After a year, this group of patients were in better health: fewer had died, fewer had complications and the quality of life was higher. Administering anticoagulants quickly was most effective mainly in those cases where the emergency services had been rung within an hour.
A larger stent
Heestermans’ research also shows that anticoagulants are effective in preventing early thrombosis in stents placed in the coronary arteries. Stent thrombosis is a potentially lethal condition which occurs in two percent of cases after angioplasty has been carried out. One in six patients afflicted by this type of thrombosis perishes. This can be prevented to some extent by not stopping treatment with clopidogrel too soon and by using a sufficiently large stent.
Curriculum Vitae
Ton Heestermans (Chaam, 1973) studied medicine in Leuven, Belgium. He conducted his research at the Medical Center Alkmaar in collaboration with the Isala hospital in Zwolle, the St Antonius hospital in Nieuwegein and the Catherina hospital in Eindhoven. He works as a cardiologist at the Medical Center Alkmaar. The title of his thesis is Antiplatelet therapy in myocardial infarction and coronary stent thrombosis. His promotor is Professor Felix Zijlsta.
Note for the press
Contact: the UMCG press office, tel. 050-361 2200, e-mail: voorlichting bvl.umcg.nl
Last modified: | 13 March 2020 01.58 a.m. |
More news
-
16 January 2025
€16,5 miljoen subsidie voor onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker
Het UMCG gaat specifieke CAR-T cellen produceren om patiënten met terugkerende beenmergkanker te behandelen. Samen met Amsterdam UMC Cancer Center Amsterdam gaat het UMCG de effectiviteit van deze mogelijk nieuwe behandeling onderzoeken. Voor het...
-
16 December 2024
Jouke de Vries: ‘The University will have to be flexible’
2024 was a festive year for the University of Groningen. Jouke de Vries, the chair of the Executive Board, looks back.
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...